Our business model
In August 2017, Shire announced that it was conducting a strategic review of its neuroscience business. Following the first stage of this review, the Board concluded that the neuroscience business warranted additional focus and investment and that there was a strong business rationale for creating two distinct business divisions within Shire: a Rare Disease division and a Neuroscience division. Each division will benefit from sharper management focus, greater strategic clarity, and an increased ability to deploy resources to key growth priorities. This divisional structure will be an important first step in enabling Shire to maximize mid- to long-term product sales, cash generation, and innovation for both businesses. The second stage of the review will include continuing to evaluate all strategic alternatives for the Neuroscience division, including the merits of an independent listing. Shire will give an update on the second stage of the review in the second half of 2018.
A rapidly changing environment |
The resources we employ |
- Era of unprecedented innovation
- Shifting demographics
- Rising expectations and competition
- Evolving customer landscape
- Political and regulatory volatility
- Increasingly targeted business models
- Focus on high impact therapies for high-need patients
|
- Talented employees and Shire culture
- Strong collaborations and partnerships
- Financial capital
- Plant and equipment
- Intellectual property
- Suppliers
|
 |
|
What makes us different
As the global leader in rare diseases with a thriving neuroscience business, Shire is a champion for those patients most in need, and is well positioned to address market trends through:
- Our long-term vision and commitment to rare diseases
- Our relentless focus on patients
- Our commitment to internal and external innovation
- Our strong brands and franchises that enable leadership
How we create value |
Rare Disease division
Global biotech leader in rare diseases |
Neuroscience division
Established market leader in neuropsychiatry |
| 2017 revenue |
|
 |
| Commercial model |
- Personalized, high-touch model
- Small field forces focused on centers of excellence
- Global focus with direct commercial presence in 60+ countries
- Strong relationships with patient groups and key opinion leaders
|
- Broad-based promotion, including direct-to-consumer
- Larger sales forces covering primary care and specialists
- Focused on U.S. and key international markets
- Specialized expertise in market development and market access
- Close relationships with key opinion leaders and providers
|
| R&D |
- Emphasis on first-in-class, breakthrough innovations, especially biologics
- Healthy innovation pipeline with more than 35 clinical programs
- Preferred partner for rare disease drug development, with multiple successful external collaborations
|
- R&D strategy focused on differentiated treatment options to meet diverse patient needs; emphasis on small molecules and lifecycle management
- Several programs under development for new indications, such as SHP680, and geographic expansion of existing brands, such as BUCCOLAM in the U.S.
|
| Operations |
- Global manufacturing footprint across 14 sites with a focus on biologics
- Infrastructure includes plasma donation centers, a plasma processing and fractionation network, and antibody development facilities
|
- Lean manufacturing model extensively levering contract manufacturing partnerships
|
|
|
Creating value for all our stakeholders
High patient impact
By focusing on diseases and patient populations with high unmet need, Shire strives to achieve the greatest positive impact among the patients who need it the most.
Sustained growth
By bringing our capabilities and expertise to underserved patient communities, we deliver sustained value for patients, employees, partners, and shareholders on a global scale.
High societal value
Working alongside partners, doctors, advocates, governments, and payers, Shire achieves meaningful outcomes that help ease the long-term burden of rare diseases and specialized conditions.
